PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance

Table 2

Comparison of clinical parameters after fenofibrate treatment for 12 and 24 weeks in patients with hypertriglyceridemia ().

Parameters	Baseline	12 weeks	24 weeks
Age, y	44.68 ± 10.51
Gender, M/F	50/32
WC, cm	93.00 ± 7.78	92.32 ± 7.26	91.27 ± 7.59
BMI, kg/m^2	25.67 ± 3.11	25.29 ± 3.44	25.08 ± 3.35
TC, mmol/L	5.34 ± 0.68	5.11 ± 0.94	5.12 ± 0.66
LDL-C, mmol/L	2.79 ± 0.75	3.10 ± 0.72	3.02 ± 0.61
HDL-C, mmol/L	1.03 ± 0.18	1.29 ± 0.27	1.40 ± 0.27
TG, mmol/L	2.70 (1.93–3.56)	1.75 (1.47–2.00)	1.63 (1.21–2.04)
FBG, mmol/L	5.43 ± 0.49	5.45 ± 0.50	5.33 ± 0.46
FINS, mIU/L	14.40 (8.85–23.45)	12.80 (8.90–17.10)	10.40 (7.10–15.40)
HOMA-IR	3.26 (2.53–5.18)	2.59 (1.98–3.85)	2.42 (1.46–4.12)
HOMA-	124.31 (65.45–194.17)	110.00 (45.38–131.58)	95.10 (48.75–123.07)

Data are means ± SD unless indicated otherwise. TG, FINS, hsCRP, HOMA-IR, and HOMA- are shown as medians and upper and lower quartiles. WC: waist circumference; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function. Significantly different at versus baseline; significantly different at versus baseline.